Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress
Revolution Medicines announced positive topline results from the Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic cancer, showing a statistically significant improvement in overall survival (13.2 months vs 6.7 months) compared to chemotherapy. The company plans to submit these data to global regulatory authorities, including the FDA, and has initiated an Expanded Access Program for eligible patients. In April 2026, the company strengthened its financial position with $2.2 billion in gross proceeds from concurrent offerings of common stock and convertible notes, ending the quarter with $1.9 billion in cash and equivalents.
Key figures
- Net Loss
- 453816000
- Revenue
- 0
- Drug Name
- daraxonrasib (RMC-6236)
- Guidance
- Full year 2026 GAAP operating expenses $1.7B-$1.8B; Stock-based compensation $260M-$280M
- Ga Expenses
- 101252000
- Rd Expenses
- 343970000
- Cash Position
- 1908084000
- Phase Of Trial
- Phase 3
- Hazard ratio
- 0.4
- Median os pdac months
- 13.2
- Proceeds from offerings
- 2225000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.